Management of Palpitations

Introduction to Treatment

• The American College of Cardiology recommends metoprolol 50 mg twice daily as an appropriate treatment option for palpitations, particularly when caused by supraventricular tachyarrhythmias or atrial fibrillation, with demonstrated efficacy for rate control and potential conversion to normal sinus rhythm in select cases 1, 2

Treatment of Specific Arrhythmias

• Metoprolol is considered reasonable for ongoing management of recurrent symptomatic multifocal atrial tachycardia (MAT) and can be used for acute treatment of MAT, particularly after correction of underlying causes 1, 3
• For atrial fibrillation, metoprolol is a Class I recommendation (Level of Evidence C) for rate control 2

Dosing and Administration

• The American Heart Association recommends metoprolol tartrate starting dose of 25 mg BID, with a maintenance dose up to 200 mg BID, while the American College of Cardiology recommends metoprolol succinate (extended-release) starting dose of 50 mg QD, with a maintenance dose up to 400 mg QD 1

• Recommended oral dosages for metoprolol are:

  Formulation	Dosage
  Metoprolol tartrate	25-100 mg BID
  Metoprolol succinate	50-400 mg QD

  3, 4, 5, 6

• Alternative therapies such as calcium channel blockers (e.g., diltiazem, verapamil), or esmolol can be considered if metoprolol is ineffective or contraindicated, with specific dosing recommendations:

  Formulation	Dosage
  Diltiazem	0.25 mg/kg IV over 2 minutes, followed by 5-15 mg/h infusion
  Verapamil	0.075-0.15 mg/kg IV over 2 minutes
  Esmolol	500 mcg/kg IV over 1 minute, followed by 50-300 mcg/kg/min infusion

  6, 7, 8, 4

Efficacy and Safety

• Metoprolol is effective for rate control in atrial fibrillation and management of symptomatic palpitations 2, 1
• Metoprolol should be used with caution in patients with severe bronchospastic pulmonary disease, asthma, COPD, compensated heart failure, and diabetes, and is contraindicated in patients with severe bradycardia, high-grade AV block (without pacemaker), cardiogenic shock, and decompensated heart failure 1, 3, 9, 6, 4, 7, 10, 5, 11
• The American College of Cardiology recommends monitoring for potential side effects including hypotension, bradycardia, and bronchospasm when initiating metoprolol 1

Special Considerations

• In patients with left ventricular ejection fraction (LVEF) ≥40%, any beta-blocker can be used at starting doses listed above, according to the European Society of Cardiology, while in patients with LVEF <40%, the smallest dose of beta-blocker should be used to achieve rate control, with metoprolol, carvedilol, or bisoprolol as preferred options 12
• In patients with heart failure and atrial fibrillation, beta-blockers remain first-line therapy, despite lack of mortality benefit, according to the European Society of Cardiology, and the smallest dose needed to achieve rate control should be targeted, with titration done gradually (typically every 2 weeks) to avoid decompensation 12
• Regular monitoring of blood pressure, heart rate, renal function, and electrolytes, particularly potassium levels, is crucial when using metoprolol in dialysis patients to avoid complications such as hypotension, bradycardia, and electrolyte imbalances 13
• Midodrine, an alpha-1 agonist, can help support blood pressure in dialysis patients and should be administered approximately 1 hour before dialysis sessions and as needed between sessions, with parameters to hold if systolic blood pressure exceeds 140 mmHg 13

Goals and Pitfalls of Treatment

• The goal of rate control is to improve symptoms and quality of life while preventing tachycardia-induced cardiomyopathy, rather than achieving a specific heart rate target, with once-daily dosing with metoprolol succinate significantly improving medication adherence compared to twice-daily regimens with metoprolol tartrate, reducing the risk of missed doses, as suggested by the European Society of Cardiology 9, 6, 10, 14
• Common pitfalls in managing atrial fibrillation in dialysis patients include increasing metoprolol too rapidly before addressing hypotension, failing to monitor for bradycardia when increasing beta-blocker dose, not considering drug interactions between rate-controlling medications, and overlooking the need for regular electrolyte monitoring 13